{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045193","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.009630+00:00","generated_at":"2026-06-07T11:15:08.296863+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bone Biologics announces 1-for-8 reverse stock split effective December 20","bullets":["Reverse stock split at 1-for-8 ratio effective 12:01 a.m. ET on December 20, 2023.","Common stock trades post-split under symbol BBLG; warrants under BBLGW.","New CUSIP for common stock is 098070501; par value remains $0.001.","Authorized shares unchanged; fractional shares rounded up to nearest whole.","Proportionate adjustments to exercise prices and shares issuable under warrants and equity awards."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045193","json":"https://secwatch.observer/filing/0001493152-23-045193.json","markdown":"https://secwatch.observer/filing/0001493152-23-045193.md","text":"https://secwatch.observer/filing/0001493152-23-045193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223045193/0001493152-23-045193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223045193/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:15:08.296863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"054fbc6a07abfeb20ea72111d8a59f08469d0f74","claim":"Bone Biologics Corp: Filed Certificate of Amendment to effect a 1-for-8 reverse stock split of common stock, effective December 20, 2023 (effective 2023-12-20).","evidence_excerpt":"On December 14, 2023, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Certificate of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-8 shares, effective as of 12:01 a.m. Eastern Time on December 20, 2023 (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223045193/0001493152-23-045193-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-20"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}